Last reviewed · How we verify

NCT07242599: ORIS

Ongericimab Injection Reducing Recurrence of Ischemic Stroke

Not yet recruiting Phase 3 Last updated 16 April 2026
What this trial tests

Phase 3 trial testing High target group in Ischemic Cerebral Infarction in 4,810 participants. Not yet recruiting.

Timeline
22 April 2026
Primary endpoint
1 April 2029
1 April 2029

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment4,810
Start date22 April 2026
Primary completion1 April 2029
Estimated completion1 April 2029
Sites199 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

18 and older, any sex, with Ischemic Cerebral Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C \< 1.4 mmol/L).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07242599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing